REGION HOVEDSTADEN

Their core work

Region Hovedstaden (Capital Region of Denmark) is the largest healthcare authority in Denmark, operating major university hospitals including Rigshospitalet and Herlev Hospital. Their H2020 participation centers on large-scale clinical research — from stem cell therapy and diabetes prevention to neuropsychiatric disorders and cancer diagnostics. They bring clinical infrastructure, patient cohorts, biobanks, and registry data to European research consortia, functioning as a bridge between hospital-based clinical practice and translational biomedical research.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Region Hovedstaden's work was broadly distributed across cognition, healthy ageing, cancer genetics, and disease prevention — reflecting a large hospital system contributing patient data and clinical expertise across many therapeutic areas. By the later period (2019–2022), a clear convergence emerged toward precision medicine: biomarkers, deep phenotyping, patient stratification, and clinical trial networks became dominant themes, particularly in diabetes and neuropsychiatric disorders. This shift signals a transition from observational cohort studies toward intervention-ready, data-driven clinical research.

Region Hovedstaden is moving decisively toward biomarker-guided patient stratification and clinical trial infrastructure, making them an increasingly valuable partner for projects that need to validate precision medicine approaches in real hospital settings.

How they like to work

Primarily a consortium partner (65 of 79 projects), but capable of leading when the topic aligns with their clinical strengths — their 14 coordinated projects include some of the largest in their portfolio (SCIENCE at EUR 3.3M, Click-It at EUR 2.2M). With 781 unique partners across 49 countries, they operate as a high-connectivity hub, rarely repeating the same consortium. This breadth makes them easy to integrate into new consortia but also means they are selective about coordination roles, typically leading only when they own the clinical infrastructure central to the project.

An exceptionally broad network of 781 unique partners across 49 countries, reflecting their role as a major clinical site that many European consortia want to include for patient access and hospital-based research infrastructure.

What sets them apart

Region Hovedstaden is not a university or research institute — it is a regional health authority running Denmark's largest hospitals, which gives it direct access to patient populations, clinical registries, and biobanks at a scale few academic partners can match. Their ability to coordinate projects worth EUR 2–3M demonstrates they can lead complex clinical trials, not just contribute data. For consortium builders, they offer something rare: a single partner that combines hospital-level clinical infrastructure with research-grade data collection across nearly every major disease area.

Highlights from their portfolio

• SCIENCE
  Largest funded project (EUR 3.3M, coordinated) — stem cell therapy for ischemic heart disease, demonstrating capacity to lead high-budget interventional clinical trials.
• Click-It
  Coordinated EUR 2.2M project on in vivo PET imaging agents, showing strength in molecular imaging and companion diagnostics development.
• INNODIA
  Major type 1 diabetes consortium (EUR 980K contribution) building biomarker platforms, biobanks, and clinical trial networks — central to their precision medicine trajectory.